| Biomarker ID | 967 |
| PMID | 22870138 |
| Year | 2011 |
| Biomarker | Osteopontin |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | PCa Vs BPH VS Healthy Donors |
| Type of Biomarker | Diagnostic |
| Cohort | PCa patients (29), benign prostate hyperplasia (BPH) (18) and control healthy donors (HD) (30) were selected for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | Antibodies against rOPN-GST were detected in 19/29 (66%), 6/18 (33%) and 3/30 (10%) plasma samples from PCa, BPH and HD, respectively |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |